Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma

Jatin J Shah
Robert Z Orlowski
Sheeba K Thomas

January 2009

Jatin J Shah1, Robert Z Orlowski1,2, Sheeba K Thomas11Departments of Lymphoma/Myeloma; 2Experimental...

Phase II Study of Neoadjuvant Gemcitabine, Pegylated Liposomal Doxorubicin, and Docetaxel in Locally Advanced Breast Cancer

ARTIOLI G
BORGATO L
CAPPETTA A
BOZZA F
ZAVAGNO G
ZOVATO S
MARCHET A
PASTORELLI D.
MOCELLIN, SIMONE

January 2010

AIM: This was a phase II study to assess the activity of a novel neoadjuvant regimen in locally-ad...

A Phase-I Study Evaluating the Combination of Pegylated Liposomal Doxorubicin and Paclitaxel as Salvage Chemotherapy in Metastatic Breast Cancer Previously Treated with Anthracycline

洪瑞隆
HONG, RUEY-LONG

June 2011

Purpose The two main goals of this phase-I study were to determine the maximum-tolerated dose (MTD) ...

Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer

Irvin Jr., William J.
Orlowski, Robert Z.
Chiu, Wing Keung
Carey, Lisa A.
Collichio, Frances A.
Bernard, Philip S.
Stijleman, Inge J.
Perou, Charles
Ivanova, Anastasia
Dees, E. Claire

January 2010

Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated lipo...

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors

Dees, E. Claire
O'Neil, Bert H.
Lindley, Celeste M.
Collichio, Frances
Carey, Lisa A.
Collins, Jason
Riordan, William J.
Ivanova, Anastasia
Esseltine, Dixie
Orlowski, Robert Z.

January 2008

Pre-clinical studies combining the proteasome inhibitor bortezomib with anthracyclines have shown en...

An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens

Parma, G
Mancari, Rosanna
Del Conte, G
Scambia, Giovanni (ORCID:0000-0003-2758-1063)
Gadducci, A
Hess, D
Katsaros, D
Sessa, C
Rinaldi, A
Bertoni, F
Vitali, A
Catapano, Cv
Marsoni, S
Van De Velde, H
Colombo, N.

January 2012

BACKGROUND: Pegylated liposomal doxorubicin (PLD) is an established treatment for relapsed ovarian c...

A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN)

Lee, Yong Jae
Seol, Aeran
Lee, Maria
Kim, Jae-Weon
Kim, Hee Seung
Kim, Kidong
Suh, Dong Hoon
Kim, Sunghoon
Kim, Sang Wun
Lee, Jung-Yun

January 2022

Background/aimThe majority of targeted therapies are focused on BRCA mutations, homologous recombina...

Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).

Rochlitz, C.
Ruhstaller, T.
Lerch, S.
Spirig, C.
Huober, J.
Suter, T.
Bühlmann, M.
Fehr, M.
Schönenberger, A.
von Moos, R.
Winterhalder, R.
Rauch, D.
Müller, A.
Mannhart-Harms, M.
Herrmann, R.
Cliffe, B.
Mayer, M.
Zaman, K.

January 2011

BACKGROUND: Pegylated liposomal doxorubicin (PLD) and bevacizumab are active agents in the treatment...

Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)

Rochlitz, C.
Ruhstaller, T.
Lerch, S.
Spirig, C.
Huober, J.
Suter, T.
Bühlmann, M.
Fehr, M.
Schönenberger, A.
von Moos, R.
Winterhalder, R.
Rauch, D.
Müller, A.
Mannhart-Harms, M.
Herrmann, R.
Cliffe, B.
Mayer, M.
Zaman, K.

August 2017

Background: Pegylated liposomal doxorubicin (PLD) and bevacizumab are active agents in the treatment...

A. Alexopoulos
M. V. Karamouzis
H. Stavrinides
A. Ardavanis
J. Stavrakakis
C. Georganta
G. Rigatos

January 2004

Background: The aim of this study was to determine the activity and safety of pegylated liposomal do...

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

Harbeck, Nadia
Saupe, Steffen
Jäger, Elke
Schmidt, Marcus
Kreienberg, Rolf
Müller, Lothar
Otremba, Burkhard Jörg
Waldenmaier, Dirk
Dorn, Julia
Warm, Mathias
Scholz, Michael
Untch, Michael
Wit, Maike de
Barinoff, Jana
Lück, Hans-Joachim
Harter, Philipp
Augustin, Doris
Harnett, Paul
Beckmann, Matthias W.
Al-Batran, Salah-Eddin

January 2017

The PELICAN trial evaluates for the first time efficacy and safety of pegylated liposomal doxorubici...

A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.

Schmid, P
Kühnhardt, D
Kiewe, P
Lehenbauer-Dehm, S
Schippinger, W
Greil, R
Lange, W
Preiss, J
Niederle, N
Brossart, P
Freier, W
Kümmel, S
Van de Velde, H
Regierer, A
Possinger, K

May 2008

BACKGROUND Proteasome inhibitors are a novel class of compounds entering clinical trials as a met...

A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer

Lang, BHH
Chow, LWC
Yip, AYS

January 2007

The objective of the present study is to investigate the clinical efficacy and tolerance of vinorelb...

Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer

R. Torrisi
A. Cardillo
G. Cancello
S. Dellapasqua
A. Balduzzi
R. Ghisini
A. Luini
P. Veronesi
G. Viale
A. Goldhirsch
M. Colleoni

January 2010

Background: Pegylated liposomal doxorubicin (PLD) was shown as active but less toxic compared to dox...

Update on treatment of follicular non-Hodgkin&rsquo;s lymphoma: focus on potential of bortezomib

Brander DM
Beaven AW

March 2012

Danielle M Brander, Anne W BeavenDuke University Medical Center, Durham, NC, USAAbstract: Follicular...

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma

Jatin J Shah
Robert Z Orlowski
Sheeba K Thomas

January 2009

Jatin J Shah1, Robert Z Orlowski1,2, Sheeba K Thomas11Departments of Lymphoma/Myeloma; 2Experimental...

Phase II Study of Neoadjuvant Gemcitabine, Pegylated Liposomal Doxorubicin, and Docetaxel in Locally Advanced Breast Cancer

ARTIOLI G
BORGATO L
CAPPETTA A
BOZZA F
ZAVAGNO G
ZOVATO S
MARCHET A
PASTORELLI D.
MOCELLIN, SIMONE

January 2010

AIM: This was a phase II study to assess the activity of a novel neoadjuvant regimen in locally-ad...

A Phase-I Study Evaluating the Combination of Pegylated Liposomal Doxorubicin and Paclitaxel as Salvage Chemotherapy in Metastatic Breast Cancer Previously Treated with Anthracycline

洪瑞隆
HONG, RUEY-LONG

June 2011

Purpose The two main goals of this phase-I study were to determine the maximum-tolerated dose (MTD) ...

Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer

Irvin Jr., William J.
Orlowski, Robert Z.
Chiu, Wing Keung
Carey, Lisa A.
Collichio, Frances A.
Bernard, Philip S.
Stijleman, Inge J.
Perou, Charles
Ivanova, Anastasia
Dees, E. Claire

January 2010

Based on preclinical studies and a phase I trial of the combination of bortezomib and pegylated lipo...

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors

Dees, E. Claire
O'Neil, Bert H.
Lindley, Celeste M.
Collichio, Frances
Carey, Lisa A.
Collins, Jason
Riordan, William J.
Ivanova, Anastasia
Esseltine, Dixie
Orlowski, Robert Z.

January 2008

Pre-clinical studies combining the proteasome inhibitor bortezomib with anthracyclines have shown en...

An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens

Parma, G
Mancari, Rosanna
Del Conte, G
Scambia, Giovanni (ORCID:0000-0003-2758-1063)
Gadducci, A
Hess, D
Katsaros, D
Sessa, C
Rinaldi, A
Bertoni, F
Vitali, A
Catapano, Cv
Marsoni, S
Van De Velde, H
Colombo, N.

January 2012

BACKGROUND: Pegylated liposomal doxorubicin (PLD) is an established treatment for relapsed ovarian c...

A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN)

Lee, Yong Jae
Seol, Aeran
Lee, Maria
Kim, Jae-Weon
Kim, Hee Seung
Kim, Kidong
Suh, Dong Hoon
Kim, Sunghoon
Kim, Sang Wun
Lee, Jung-Yun

January 2022

Background/aimThe majority of targeted therapies are focused on BRCA mutations, homologous recombina...

Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).

Rochlitz, C.
Ruhstaller, T.
Lerch, S.
Spirig, C.
Huober, J.
Suter, T.
Bühlmann, M.
Fehr, M.
Schönenberger, A.
von Moos, R.
Winterhalder, R.
Rauch, D.
Müller, A.
Mannhart-Harms, M.
Herrmann, R.
Cliffe, B.
Mayer, M.
Zaman, K.

January 2011

BACKGROUND: Pegylated liposomal doxorubicin (PLD) and bevacizumab are active agents in the treatment...

Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)

Rochlitz, C.
Ruhstaller, T.
Lerch, S.
Spirig, C.
Huober, J.
Suter, T.
Bühlmann, M.
Fehr, M.
Schönenberger, A.
von Moos, R.
Winterhalder, R.
Rauch, D.
Müller, A.
Mannhart-Harms, M.
Herrmann, R.
Cliffe, B.
Mayer, M.
Zaman, K.

August 2017

Background: Pegylated liposomal doxorubicin (PLD) and bevacizumab are active agents in the treatment...

A. Alexopoulos
M. V. Karamouzis
H. Stavrinides
A. Ardavanis
J. Stavrakakis
C. Georganta
G. Rigatos

January 2004

Background: The aim of this study was to determine the activity and safety of pegylated liposomal do...

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

Harbeck, Nadia
Saupe, Steffen
Jäger, Elke
Schmidt, Marcus
Kreienberg, Rolf
Müller, Lothar
Otremba, Burkhard Jörg
Waldenmaier, Dirk
Dorn, Julia
Warm, Mathias
Scholz, Michael
Untch, Michael
Wit, Maike de
Barinoff, Jana
Lück, Hans-Joachim
Harter, Philipp
Augustin, Doris
Harnett, Paul
Beckmann, Matthias W.
Al-Batran, Salah-Eddin

January 2017

The PELICAN trial evaluates for the first time efficacy and safety of pegylated liposomal doxorubici...

A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines.

Schmid, P
Kühnhardt, D
Kiewe, P
Lehenbauer-Dehm, S
Schippinger, W
Greil, R
Lange, W
Preiss, J
Niederle, N
Brossart, P
Freier, W
Kümmel, S
Van de Velde, H
Regierer, A
Possinger, K

May 2008

BACKGROUND Proteasome inhibitors are a novel class of compounds entering clinical trials as a met...

A phase II trial of vinorelbine and pegylated liposomal doxorubicin in patients with pretreated metastatic breast cancer

Lang, BHH
Chow, LWC
Yip, AYS

January 2007

The objective of the present study is to investigate the clinical efficacy and tolerance of vinorelb...

Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer

R. Torrisi
A. Cardillo
G. Cancello
S. Dellapasqua
A. Balduzzi
R. Ghisini
A. Luini
P. Veronesi
G. Viale
A. Goldhirsch
M. Colleoni

January 2010

Background: Pegylated liposomal doxorubicin (PLD) was shown as active but less toxic compared to dox...

Update on treatment of follicular non-Hodgkin&rsquo;s lymphoma: focus on potential of bortezomib

Brander DM
Beaven AW

March 2012

Danielle M Brander, Anne W BeavenDuke University Medical Center, Durham, NC, USAAbstract: Follicular...

Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma

Jatin J Shah
Robert Z Orlowski
Sheeba K Thomas

January 2009

Jatin J Shah1, Robert Z Orlowski1,2, Sheeba K Thomas11Departments of Lymphoma/Myeloma; 2Experimental...

Phase II Study of Neoadjuvant Gemcitabine, Pegylated Liposomal Doxorubicin, and Docetaxel in Locally Advanced Breast Cancer

ARTIOLI G
BORGATO L
CAPPETTA A
BOZZA F
ZAVAGNO G
ZOVATO S
MARCHET A
PASTORELLI D.
MOCELLIN, SIMONE

January 2010

AIM: This was a phase II study to assess the activity of a novel neoadjuvant regimen in locally-ad...

A Phase-I Study Evaluating the Combination of Pegylated Liposomal Doxorubicin and Paclitaxel as Salvage Chemotherapy in Metastatic Breast Cancer Previously Treated with Anthracycline

洪瑞隆
HONG, RUEY-LONG

June 2011

Purpose The two main goals of this phase-I study were to determine the maximum-tolerated dose (MTD) ...

Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer

Abstract

Extracted data

Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer

Abstract

Extracted data

Topics

Related items

Topics

Related items